Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:BSX
Previous Symbol
CUSIP10113710
Phone508-683-4000
Debt
Debt-to-Equity Ratio0.58
Current Ratio0.78
Quick Ratio0.56
Price-To-Earnings
Trailing P/E Ratio24.68
Forward P/E Ratio24.50
P/E Growth2.32
Sales & Book Value
Annual Sales$9.05 billion
Price / Sales5.21
Cash Flow$1.8277 per share
Price / Cash18.63
Book Value$5.99 per share
Price / Book5.68
Profitability
EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins6.93%
Return on Equity26.44%
Return on Assets10.16%
Miscellaneous
Employees29,000
Outstanding Shares1,383,800,000
Market Cap$48.83 billion
OptionableOptionable
Boston Scientific (NYSE:BSX) Frequently Asked Questions
What is Boston Scientific's stock symbol?
Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
How were Boston Scientific's earnings last quarter?
Boston Scientific Co. (NYSE:BSX) released its quarterly earnings data on Wednesday, October, 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.01. The medical equipment provider earned $2.39 billion during the quarter, compared to analyst estimates of $2.40 billion. Boston Scientific had a net margin of 6.93% and a return on equity of 26.44%. Boston Scientific's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.31 EPS. View Boston Scientific's Earnings History.
When is Boston Scientific's next earnings date?
What guidance has Boston Scientific issued on next quarter's earnings?
Boston Scientific updated its FY18 earnings guidance on Wednesday, October, 24th. The company provided earnings per share (EPS) guidance of $1.38-1.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.40. The company issued revenue guidance of $9.787-9.827 billion, compared to the consensus revenue estimate of $9.84 billion.Boston Scientific also updated its FY 2018 guidance to $1.38-1.40 EPS.
What price target have analysts set for BSX?
24 equities research analysts have issued 1-year target prices for Boston Scientific's stock. Their forecasts range from $27.00 to $48.00. On average, they anticipate Boston Scientific's stock price to reach $39.5417 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View Analyst Price Targets for Boston Scientific.
What is the consensus analysts' recommendation for Boston Scientific?
24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 18 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific.
What are Wall Street analysts saying about Boston Scientific stock?
Here are some recent quotes from research analysts about Boston Scientific stock:
- 1. BTIG Research analysts commented, "Although top-line metrics were less pristine in several areas (Neuromod, Cardiovascular), organic revenue growth improved by 80bps from Q2 to Q3. In addition, BSX absorbed a greater f/x headwind ($40M) than initially estimated in July, skewing down reported sales and Q4 guidance. EBIT was again a bright spot with GM well ahead of expectations on improving mix. Q3 results aside, there were no changes to strategy or the 2019 outlook since bullish commentary at TCT. We see little risk to the BSX story with underlying FY19 guidance out of the way, the imminent return of Heart trending ahead of expectations, and litigation seemingly in BSX’s favor (for now). We maintain Buy and $45 PT." (10/25/2018)
- 2. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company Augmenix for $500M cash up front and up to $100M in milestones. Augmenix’s SpaceOAR reduces side effects associated with prostate radiotherapy. BSX expects the deal to be immaterial to its adjusted EPS through 2019 and increasingly accretive beginning in 2020. The SpaceOAR hydrogel is CE Marked and FDA cleared and serves an estimated $750M market. We expect the deal to strengthen BSX’s Urology & Pelvic Health business. We expect BSX’s string of acquisitions in 2018 (including Augmenix) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating and raise our price target to $43 from $39." (9/7/2018)
- 3. According to Zacks Investment Research, "Boston Scientific's delay in the relaunch of the Lotus range of heart devices is expected to hamper sales in 2018 too. We are also concerned about the declining worldwide pacemaker sales hurting Boston Scientific’s CRM business. A competitive market also adds to the woes. However, the company has been gaining from impressive growth across all its business lines and geographies. The 2018 view also paints a bright picture for the near term. Boston Scientific achieved clinical milestones for Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure device. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. Lately, the company announced several strategic acquisitions including NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy, Securus in EP and Millipede in Structural Heart. Overall, Boston Scientific outperformed its industry in a year’s time." (7/17/2018)
Has Boston Scientific been receiving favorable news coverage?
News headlines about BSX stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Boston Scientific earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of Boston Scientific's key competitors?
Some companies that are related to Boston Scientific include 3M (MMM), Becton Dickinson and (BDX), Stryker (SYK), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), ICU Medical (ICUI), Insulet (PODD) and Penumbra (PEN).
Who are Boston Scientific's key executives?
Boston Scientific's management team includes the folowing people:
- Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
- Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
- Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
- Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
- Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)
Who are Boston Scientific's major shareholders?
Boston Scientific's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.94%), BlackRock Inc. (8.12%), Capital World Investors (6.49%), Primecap Management Co. CA (3.24%), Janus Henderson Group PLC (2.91%) and Bollard Group LLC (2.43%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.
Which institutional investors are selling Boston Scientific stock?
BSX stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Deutsche Bank AG, TIAA CREF Investment Management LLC, Putnam Investments LLC, Standard Life Aberdeen plc, Bank of New York Mellon Corp, Mitsubishi UFJ Trust & Banking Corp and Janus Henderson Group PLC. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.
Which institutional investors are buying Boston Scientific stock?
BSX stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, FMR LLC, Massachusetts Financial Services Co. MA, BlackRock Inc., Point72 Asset Management L.P., Epoch Investment Partners Inc., Alliancebernstein L.P. and Capital International Investors. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.
How do I buy shares of Boston Scientific?
Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Boston Scientific's stock price today?
One share of BSX stock can currently be purchased for approximately $34.05.
How big of a company is Boston Scientific?
Boston Scientific has a market capitalization of $51.49 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.
What is Boston Scientific's official website?
How can I contact Boston Scientific?
Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]
MarketBeat Community Rating for Boston Scientific (NYSE BSX)
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
